KMDA
HOLD / NEUTRALTrendComposite
44.20
Technical
46.20
Fundamental
41.80
Rank
—
Price
7.58
Hurst
0.63
As of
Aug 17, 2026
Daily
Kamada Ltd.
HealthcareDrug Manufacturers - Specialty & GenericKamada Ltd. manufactures plasma-derived protein therapeutics used for post-exposure and post-transplant prophylaxis, immune disorders, and hemostatic conditions, with products including rabies immunoglobulin, cytomegalovirus prophylaxis, varicella treatment, and clotting factor replacements. The company also distributes a range of biopharmaceutical medications in Israel covering respiratory diseases, allergies, rheumatologic conditions, infectious diseases, and oncology. Based in Rehovot, Israel, Kamada was established in 1990.
Market cap
$444.4M
P/E (trailing)
20.26
P/E (forward)
13.35
PEG ratio
0.61
Dividend yield
221.00%
Beta
0.13
52w range
6.55 – 9.35
Return on equity
+8.40%
Profit margin
+11.60%
Revenue growth
+22.70%
Earnings growth
+23.10%
Price history
1Y: 7.70 (+17.0%) · range 6.29–8.87
Cycle position
44/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 34 · NOT READY · exit proximity 0
Conviction
26/ 100 · maturity 0%
Buildup.335
EMA entry setup.4234
Fundamentals.2542
Volume profile
POC
8.26
Price vs POC
-6.8%
Overhead supply
59%
Runway
+0.3%
Value area 7.12–8.47 · 59% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +6.41% | +12.33% | mature |
| 40d | +1.15% | +16.67% | mature |